Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Avoiding tolerance against prostatic antigens with subdominant peptide epitopes.

M E Grossmann1, T Davila, T Celis

  • 1Department of Urology, Mayo Clinic/Foundation, Rochester, Minnesota 55905, USA. grossmann.michael@mayo.edu

Journal of Immunotherapy (Hagerstown, Md. : 1997)
|June 8, 2001
PubMed
Summary

Overcoming immune tolerance to prostate-associated antigens (PAA) is key for cancer immunotherapy. Subdominant epitopes, not dominant ones, successfully induced immune responses in a mouse model, offering a promising strategy for prostate cancer treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of radiology in obstetrics.

The Practitioner·2010
Same author

Effect of obesity on breast cancer development.

Veterinary pathology·2010
Same author

Effects of adiponectin on breast cancer cell growth and signaling.

British journal of cancer·2008
Same author

Forced expression of heat-shock protein 70 increases the secretion of Hsp70 and provides protection against tumour growth.

British journal of cancer·2004
Same author

Expression, specificity and immunotherapy potential of prostate-associated genes in murine cell lines.

World journal of urology·2002
Same author

Androgen receptor signaling in androgen-refractory prostate cancer.

Journal of the National Cancer Institute·2001

Area of Science:

  • Immunology
  • Oncology
  • Cancer Immunotherapy

Background:

  • Prostate cancer immunotherapy aims to induce immune responses against prostate-associated antigens (PAA).
  • Pre-existing immune tolerance to PAA poses a significant challenge for developing effective immunotherapies.
  • The transgenic adenocarcinoma mouse prostate (TRAMP) model expresses SV40T antigen in the prostate, serving as a model for studying tolerance.

Purpose of the Study:

  • To evaluate mechanisms for overcoming immune tolerance to PAA in the context of prostate cancer immunotherapy.
  • To assess the immunogenicity of dominant and subdominant epitopes of SV40T antigen in TRAMP mice.

Main Methods:

  • Assessed immune tolerance to SV40T antigen in TRAMP mice compared to nontransgenic littermates.
  • Administered CpG oligonucleotides and anti-CD40 antibodies to evaluate their ability to overcome tolerance.

Related Experiment Videos

  • Tested the immunogenicity of a subdominant epitope of SV40T antigen in TRAMP mice.

    • Main Results:

    • TRAMP mice exhibited tolerance to a dominant cytotoxic T-lymphocyte (CTL) epitope of SV40T antigen from 4 to 24 weeks of age.
    • CpG oligonucleotides induced hematopoiesis but did not overcome tolerance.
    • Anti-CD40 antibody increased CTL response in normal mice but failed to overcome tolerance in TRAMP mice.
    • Administration of a subdominant epitope successfully circumvented tolerance in TRAMP mice.

    Conclusions:

    • Immune tolerance to dominant PAA epitopes is a significant barrier in prostate cancer immunotherapy.
    • Subdominant epitopes hold potential for inducing anti-tumor immune responses and overcoming tolerance.
    • Further investigation into subdominant epitopes could facilitate the development of novel immune-based therapies for prostate cancer.